⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Pemvidutide (Pemvidutide) | 加速させる、線維化研究を

Home/Drugs/Pemvidutide

Pemvidutide

Pemvidutide

Phase 2b

Sponsor: Altimmune

Indication: MASH / Obesity

Mechanism of Action

GLP-1/Glucagon Dual Agonist

Target: GLP-1Target: Glucagon

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT05006885

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Phase:PHASE1Org:Altimmune, Inc.

COMPLETED

Relevant Publications (PubMed)

No recent publications found for Pemvidutide.

Validated Models

This drug has been validated in the following preclinical models:

NCT05292911

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Phase:PHASE1Org:Altimmune, Inc.

COMPLETEDNCT04972396

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Phase:PHASE1Org:Altimmune, Inc.

RECRUITINGNCT07009860

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Phase:PHASE2Org:Altimmune, Inc.

ACTIVE_NOT_RECRUITINGNCT06987513

RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Phase:PHASE2Org:Altimmune, Inc.

View all trials on ClinicalTrials.gov